OC 601
Alternative Names: OC-601Latest Information Update: 28 Sep 2025
At a glance
- Originator Oncocross
- Class Anti-infectives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Infections
Most Recent Events
- 28 Sep 2025 No recent reports of development identified for preclinical development in Infections in South Korea
- 12 Aug 2021 Preclinical trials in Infections in South Korea (unspecified route) (Oncocross Pipeline, August 2021)